ProPharma
Revolutionizing the Traditional CRO Model with RCO

Since the end of the 20th century, the success of biotech, pharmaceutical, and device firms has largely relied on the efficacy of traditional clinical research organization (CRO) models built on the back of blockbuster therapies. CROs were considered the best outsourcing solution to help sponsors develop and commercialize their products without the related investment in infrastructure. They had well-proven procedures to assist large biopharma companies in various aspects of clinical trial delivery.

However, smaller biotech and pharmaceutical players developing novel therapies for rare, orphan, or other more nuanced diseases require more personalized, strategic, and tailored support throughout the product development lifecycle, which can be challenging for traditional CROs. This shift in the landscape necessitates a new degree of personalization and agility to guide and support pharmaceutical and biotechnology companies during the drug and device development process. This has led to the emergence of the Research Consulting Organization or RCO.

The world’s largest RCO, ProPharma, partners with clients across the product lifecycle through an advise-build-operate model. Unlike traditional CROs, it offers profound scientific and technological experience, delivering fit-for-purpose solutions for each sponsor’s demands at any stage of their development continuum.

ProPharma has deep domain expertise in regulatory sciences, clinical research solutions, quality and compliance, pharmacovigilance, medical information, and R&D technology. This allows the company to customize and deliver a ‘3D printed’ experience, helping clients design consulting solutions that can successfully navigate the increasingly complex global regulatory environment.

“We lead with strategy and help our partners optimize the probability of successful approval, reimbursement, and uptake by translating those requirements into a tailored solution and then bringing in the right subject matter and operational expertise to help develop and execute the plan,” says Bryan Katz, Chief Strategy Officer/Head of Corporate Development at ProPharma.

The firm’s end-to-end suite of consulting solutions de-risks and accelerates high-profile drug and medical device programs, ultimately improving patient health and safety.

“The fundamental difference between our model and a traditional CRO is that we do not bolt all these services onto a clinical trial. Conversely, we partner with our clients at an asset level and assist them wherever they are in their product’s lifecycle, advising on and operating clinical trials as needed,” says Katz.

Overall asset and client needs are central to ProPharma. For instance, it served as the go-to regulatory shop for a mid-sized European biotech customer, working with them on regulatory strategy. During that phase, ProPharma noticed that their present CRO was facing difficulties delivering the clinical trials. It stepped in, providing the right expertise from a clinical research perspective. The company continues to assist them in the RCO space today.

ProPharma’s exceptional entrepreneurial culture sets it apart from rivals and empowers its service line leadership to make the best choices for businesses, enhancing overall capacity to holistically serve customers and patients.

A leader in the industry, ProPharma collaborates with clients to co-create the best solutions by offering specialized subject matter experts, top-notch strategists, and committed program managers to reduce delays and drive consistency for end-to-end quality.